Pancreas ductal adenocarcinoma (PDAC) has one of the worst 5-year survival rates of all solid tumors, and thus new treatment strategies are urgently needed. Here, we report that targeting Bruton tyrosine kinase (BTK), a key B-cell and macrophage kinase, restores T celldependent antitumor immune responses, thereby inhibiting PDAC growth and improving responsiveness to standard-of-care chemotherapy. We report that PDAC tumor growth depends on cross-talk between B cells and FcRγ + tumor-associated macrophages, resulting in T H 2-type macrophage programming via BTK activation in a PI3Kγ-dependent manner. Treatment of PDAC-bearing mice with the BTK inhibitor PCI32765 (ibrutinib) or by PI3Kγ inhibition reprogrammed macrophages toward a T H 1 phenotype that fostered CD8 + T-cell cytotoxicity, and suppressed PDAC growth, indicating that BTK signaling mediates PDAC immunosuppression. These data indicate that pharmacologic inhibition of BTK in PDAC can reactivate adaptive immune responses, presenting a new therapeutic modality for this devastating tumor type.
INTRODUCTION
The contribution of tissue-resident and recruited leukocytes to the progression of solid tumors is now a widely accepted mechanism of pathogenesis ( 1, 2 ) , and one that is gaining notable traction in the clinic ( 3 ) . Although many studies have dissected the numerous activities leukocytes exert toward regulating neoplastic progression, tractable immune-based targets for anticancer therapy are only just emerging.
Ductal adenocarcinoma of the pancreas (PDAC) is a devastating disease with one of the lowest 5-year survival rates of all solid tumors ( 4 ) . Currently, 7.2% of patients with newly diagnosed pancreatic cancer will survive 5 years following diagnosis, due in part to the fact that PDAC is rarely detected at an early stage; instead, the majority of patients present with locally unresectable or metastatic disease ( 5 ) . Because standard therapies have only a modest impact on survival ( 6, 7 ) , novel therapeutic and diagnostic strategies are urgently needed.
A characteristic feature of PDAC tumors is the presence of abundant infi ltrating leukocytes representing both lymphoid and myeloid lineages ( 8 ) ; thus, we sought to identify functionally signifi cant immune-based programs regulating pancreatic carcinogenesis that would be tractable for therapeutic intervention. We report here that B cell-macrophage interactions promote PI3Kγ-and Bruton tyrosine kinase (BTK)-dependent macrophage T H 2 polarization, leading to immune suppression and PDAC progression. Using mouse models of PDAC, targeted inhibition of BTK, a common signaling molecule in B cells and myeloid cells, resulted in slowed PDAC tumor growth, abated immune suppression, impeded late-stage tumor growth, and improved responsiveness to standard-of-care chemotherapy (CTX), indicating that targeting BTK therapeutically could provide long-term antitumor control for this devastating malignancy.
RESULTS

B Cells and FcRf-Positive Cells in Human PDAC
We previously identifi ed a protumorigenic role for CD20 + B cells in solid tumors using murine models of squamous cell carcinogenesis, and demonstrated that therapeutic depletion of B cells in squamous cell carcinoma (SCC )-bearing mice resulted in an improved response to CTX by CD8 + T cell-dependent mechanisms ( 9 ) . To identify which human solid tumors might be regulated by protumorigenic B cells, we examined cDNA microarrays of ∼3,000 human tumors to assess levels of CD20 and immunoglobulin ( Ig ) mRNA expression
B Cells and FcRf-Positive Myeloid Cells Foster PDAC Tumorigenesis
To test the hypothesis that B cells collaborate with myeloid cells to promote PDAC tumorigenesis, we investigated tumor growth of two syngeneic murine PDAC cell lines derived from primary pancreatic carcinomas of transgenic Pdx-Cre; LSL-Kras G12D mice (10) (11) (12) harboring null mutations in p16 Ink4a (Ink4 2.2) or Trp53 (p53 2.1.1; refs. [13] [14] [15] [16] . Both cell lines generated PDACs that were histologically similar to PDACs from the transgenic mice from which they were derived ( Supplementary Fig. S2A-S2C ). PDAC tumors derived from both cell lines also exhibited similar infi ltration by CD45
+ leukocytes as a percentage of viable cells in tumors ( Fig. 2A ; Supplementary Fig. S2D + precursor stage ( 17 ) . Tumor cells were also implanted into Ig receptor FcRγ-profi cient (FcRγ +/− or +/+ ) and FcRγ-defi cient ( −/− ) mice ( 18 ) , and tumor growth kinetics and characteristics were evaluated longitudinally ( Fig. 2C and D ; Supplementary Fig. S2B and S2C ). PDACs grown in either B cell-defi cient or FcRγ-defi cient mice were signifi cantly smaller than littermate controls ( Fig. 2C and D ) and exhibited signifi cantly reduced desmoplasia, as determined by alpha smooth muscle actin (αSMA) immunoreactivity ( Fig. 2C and D ) and Gomori trichrome staining (Supplementary Fig. S2B and S2C ).
Similar to human PDAC expression of FCGR1 , FCGR2B , and FCGR3B mRNAs ( 
CD11c
+ DCs from Ink4 2.2-derived PDAC tumors harvested from FcRγ-profi cient versus FcRγ-defi cient mice, and evaluated a panel of characteristic T H 1 ( Il12b , Cd40 , Ccl5 , Tap2 , Batf , Flt3 , Ccl7 , Socs2 ) and T H 2 ( Il4ra , Arg1 , Ido1 ) mRNAs. We found signifi cant skewing of both cell types toward a T H 1 phenotype in FcRγ-defi cient mice ( Fig. 2E ). These data, together with diminished PDAC growth observed in B cell-null JH −/− mice and Ig receptornull FcRγ −/− mice, thus supported the hypothesis that B cells, as well as subsets of myeloid cells, infl uence PDAC tumor growth.
B Cell and Myeloid Cell Signaling Pathways in PDAC
Based on these fi ndings and our previous data indicating that B cells and tumor-associated macrophages impede cytotoxic T-cell (CTL) activity to regulate solid tumor development ( 19, 20 ) , we hypothesized that inhibitors of common signaling pathways active in both B cells and infi ltrating macrophages, such as BTK or PI3K signaling, might be effi cacious against PDAC tumors ( Fig. 3A and B ) . BTK is a member of the TEC family of cytoplasmic protein tyrosine kinases expressed by multiple hematopoietic-lineage cells; in B lymphocytes, BTK is activated by the B cell receptor (BCR) pathway, whereas in macrophages, BTK is activated downstream of FcRγ by spleen tyrosine kinase (Syk; refs. 21, 22 ( n = 5), and islet cell carcinomas (Islet Cell Ca; n = 6), as compared with healthy pancreas tissue ( n = 17) assessed by Affymatrix Human U133 Plus 2 microarrays. Data are represented as box-and-whisker plots depicting median fold-change value compared with normal tissue, displaying the fi rst and third quartiles at the end of each box, with the maximum and minimum at the ends of the whiskers. Statistical signifi cance was determined via the Wilcoxon rank-sum test with *, P < 0.05; ***, P < 0.001. B, FACS quantitation of CD45 + cells as a percentage of viable cells from pancreas tissues refl ecting healthy (H) pancreata ( n = 6), pancreas tissue adjacent to PDAC (Adj; n = 13), PDAC tumor margins (M; n = 4) and tumor centers (Ctr; n = 23) from patients who had not received prior chemotherapy (−CTX), and PDACs ( n = 3) from patients treated with standard-of-care CTX (+CTX). Each data point refl ects an individual piece of tissue. C, leukocyte complexity of healthy human pancreas ( n = 6), and pancreas tissue isolated from patients with PDAC evaluated by polychromatic fl ow cytometry of single-cell suspensions and evaluated for expression of the lineage markers shown. Data represent mean leukocyte complexity for leukocyte lineages shown (right) in tumor tissue resected from healthy pancreata (H; n = 6), pancreata tissue adjacent to PDAC (Adj; n = 13), tissue resected from PDAC margins ( n = 4) or tumor centers (Ctr; n = 23), and PDACs ( n = 3) from patients treated with standard-of-care CTX (+CTX). Data refl ecting individual populations is provided in Supplementary Fig. S1D . D, mRNA expression of FcγR isoforms from humans with healthy pancreas versus patients with PDAC tumors. Data were compiled from gene expression available in Oncomine (https:// www.oncomine.org ). P values and fold change in gene expression are shown. E, FACS histogram showing relative frequency of CD64 (FcγR1) and CD16 (FcγRIII) expression on leukocytes infi ltrating human PDAC. Data shown are refl ective of 20 human PDACs. Lineage markers for cell types shown are as indicated in C and refl ect basophils (baso), mast cells, macrophages (macs), DCs, infl ammatory monocytes (iMCs), eosinophils (eos), monocytes (monos), and neutrophils (neut). Adjacent (Adj) normal indicates tissue isolated from pancreas tissue proximal to resected PDAC tumors. 
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+ B cells, and CD11b + and colony-stimulating factor 1 receptor (CSF1R)-positive myeloid cells ( Fig. 3C ; Supplementary Fig. S3A ). In murine PDAC tumors, we identifi ed activated BTK (pBTK) cells in single-cell suspensions, most prominently in tumor-resident CD19 + MHCII + B cells and CD11b
+ myeloid cells ( Fig. 3D ). Relative to unstimulated cells, the mean fl uorescent intensity (MFI) of pBTK signifi cantly increased in B cells and myeloid cells following BCR and FcγRII/III stimulation, respectively ( Supplementary  Fig. S3B ). Importantly, BTK activation was reduced in FcRγ-defi cient myeloid cells infi ltrating orthotopic PDAC tumors ( Fig. 3E ) . As macrophage depletion via administration of a depleting colony-stimulating factor (CSF1) antibody (αCSF1 mAb; refs. 9 , 20 , 23 ; Supplementary Fig. S3C ) and B-cell depletion through loss of the JH locus ( 
PI3Kg Activates Macrophage BTK to Promote PDAC Growth
As PI3Ks can activate BTK to promote phospholipase C (PLC)γ-dependent signaling in hematopoietic cells ( 21 , 24 ), we explored the roles of BTK and PI3Ks in B cell-macrophage interactions during PDAC tumorigenesis. Four unique isoforms of class I PI3Ks (p110α, β, δ, and γ) regulate PI3K signaling in cells ( 2 ) . We found that primary murine macrophages express high levels of BTK and PI3Kγ (p110γ), but lower levels of PI3Kδ (p110δ), whereas B cells express high levels of BTK, PI3Kα (p110α), and PI3Kδ, but low levels of PI3Kγ; neoplastic PDAC tumor cells express only PI3Kα and PI3Kβ (p110β; Fig.  3F ; Supplementary Fig. S3D ). As PI3Kγ and BTK are similarly expressed in myeloid cells, and the PI3K isoform p110γ selectively promotes PLCγ-dependent integrin α4β1 activation leading to myeloid cell recruitment to tumors ( 25 ), we speculated that PI3Kγ might activate BTK to promote myeloid cell recruitment during PDAC progression.
To characterize the interactions between PI3Kγ and BTK in myeloid cells, we fi rst compared their roles in mediating integrin α4β1 activation and cell adhesion, processes that are required for myeloid cell traffi cking into tumors ( 25, 26 ) . To achieve this, we used pharmacologic inhibitors and siRNAmediated knockdown of Btk , as well as pharmacologic and genetic disruption of p110γ (PI3Kγ). To inhibit BTK, we utilized an FDA-approved BTK inhibitor, PCI-32765 (ibrutinib; ref. To inhibit p110γ, we utilized the investigational PI3Kγ/δ inhibitor TG100-115, which has an IC 50 of 83 nmol/L for PI3Kγ, 238 nmol/L for PI3Kδ, and >1,000 nmol/L for PI3Kα and PI3Kβ ( 25 , 28 ) .
We previously found that stromal cell-derived factor 1 (SDF1)α and IL1β induce adhesion of primary macrophages to vascular cell adhesion protein (VCAM)1-coated surfaces ( 21-23 ); both PCI-32765 and TG100-115 signifi cantly suppressed SDF1-and IL1β-mediated cell adhesion, with IC 50 values of 10 nmol/L and 100 nmol/L, respectively ( Fig. 4A and B ). In support of these fi ndings, Btk knockdown (Supplementary Fig. S4A ), similar to p110g deletion and knockdown (21) (22) (23) , suppressed adhesion of primary myeloid cells to VCAM1 ( Fig. 4C ). PCI-32765 and p110γ inhibition also suppressed CD11b + myeloid cell adhesion to vascular endothelial cell (EC) monolayers ( Supplementary Fig. S4B ), and PCI-32765 also suppressed B-cell adhesion to EC ( Supplementary Fig.  S4C ). In addition, siRNA-mediated knockdown of PLCγ2, a key BTK and PI3Kγ signaling intermediate ( 21 , 25 ; see schematic in Fig. 3A and B ), suppressed myeloid cell adhesion (Supplementary Fig. S4D and S4E ). Together, these fi ndings support the hypothesis that PI3Kγ, BTK, and PLCγ2 regulate similar signaling pathways in myeloid cells that contribute to PDAC progression.
Based on these fi ndings, we surmised that PI3Kγ might activate a BTK-signaling pathway to promote integrin α4β1 activation on macrophages prior to cell adhesion. In support of this, BTK inhibition, similar to PI3Kγ inhibition ( 25 ) , suppressed integrin activation, as measured by cytokine-induced fl uorescent VCAM1 binding to myeloid cells ( Fig. 4D ). In this assay, whereas VCAM1 binding to macrophages was rapidly stimulated by SDF1α or positive control Mn 2+ , VCAM1 binding was completely inhibited in the presence of PCI-32765 ( Fig. 4D ) . Because BTK activation, as measured by autophosphorylation on Y223, was suppressed in macrophages lacking PI3Kγ (p110γ −/− ; Supplementary Fig. S4F ), we concluded that PI3Kγ activates a BTK-PLCγ2 pathway to promote integrin activation, myeloid cell adhesion and, potentially, myeloid cell recruitment to tumors in vivo .
Because we previously reported that PI3Kγ regulates protumorigenic properties of macrophages in vivo ( 25 ), we asked whether PI3Kγ activated BTK to promote protumor macrophage polarization. IFNγ/lipopolysaccharide (LPS) signaling induces macrophage expression of T H 1 cytokines, including IL12, TNFα, IL6, IL1β, and nitric oxide synthase (NOS)2, and inhibits expression of T H 2 immune-suppressive cytokines, including Arginase (ARG)1 and TGFβ in vitro , whereas IL4 signaling instead inhibits expression of T H 1 cytokines and stimulates expression of T H 2 factors in vitro ( 29, 30 ) . We undertook an analysis of relative mRNA levels in IFNγ-or IL4-stimulated control and p110g −/− or PCI-32765-treated macrophages by RT-PCR. Analysis of the change in mRNA levels between control and p110g −/− or PCI-32765-treated macrophages indicated that genetic or pharmacologic inhibition of either PI3Kγ or BTK induced T H 1 skewing of IFNγ/LPS-stimulated macrophages, as expression of Il12 , Il6 , Tnfa, Il1b , and Nos2 was enhanced, and expression of Arg1, Il10 , and Ccl2 was reduced ( Fig. 4E ; Supplementary Fig. S4G and S4H). Inhibition of either PI3Kγ or BTK by pharmacologic or genetic approaches similarly induced T H 1 skewing of IL4-stimulated macrophages while also inhibiting Il1b and Tnfa expression ( Fig. 4F ; Supplementary Fig. S4I ). The combination of BTK inhibitors with PI3Kγ −/− macrophages had little additional effect on T H 1 skewing of macrophage gene expression profi les ( Fig. 4F ), indicating that BTK and PI3Kγ regulate similar macrophage polarization pathways. Importantly, these observations also reveal that PI3Kγ and BTK similarly promote T H 2 macrophage polarization and restrain T H 1 polarization, indicating that these kinases may promote protumor T H 2 macrophage polarization in vivo .
Because macrophage FcγR signaling promotes PDAC growth ( −/− or PCI-32765-treated primary murine macrophages ( n = 3). I, relative mRNA expression of macrophages cocultured in p53 2.1.1 tumor cell-conditioned medium (TCM) with tumor-derived B cells ( n = 3) or PCI-32765-treated B cells. Data shown are mean ± SEM of biological replicates and were validated in 3 or more separate experiments. Signifi cance testing was performed by one-way ANOVA with Tukey post hoc testing for multiple pairwise testing or by the Student t test, where P > 0.05 unless other specifi ed; *, P < 0.05; **, P < 0.01; ***, P < 0.001. For mRNA expression studies, P < 0.01 unless otherwise indicated. 
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macrophages with anti-FcγR antibodies followed by secondary antibodies. FcγR cross-linking of IL4-polarized macrophages enhanced T H 2 skewing, as macrophages displayed enhanced expression of key T H 2 factors, including Arg1 and Ccl2 ( Fig. 4G ) . Importantly, inhibition of either PI3Kγ or BTK suppressed FcγR-stimulated T H 2 cytokine expression and promoted T H 1 cytokine expression, with the exception that PI3Kγ inhibition suppressed, while BTK inhibition stimulated, Tnfa and Il1b expression ( Fig. 4H ) . These minor differences in FcγR-stimulated gene expression indicate that PI3Kγ regulates both BTK-dependent and BTK-independent gene expression pathways. Taken together, these results support the hypothesis that PI3Kγ activates BTK to promote macrophage T H 2 polarization. We previously reported that B cell-derived Ig containing immune complexes stimulate FcγR cross-linking to promote macrophage T H 2 cytokine expression ( 19 ) . To determine if BTK regulated B cell-directed expression of T H 2 cytokines in macrophages, we cocultured PDAC-derived B cells with primary macrophages in coculture chambers in vitro . Under these conditions, B cells and macrophages were separated by a fi lter allowing the passage of only macromolecules between chambers. In the presence of PDAC cell-conditioned medium, tumor-derived B cells enhanced macrophage T H 2 skewing; however, pretreatment of PDAC-derived B cells with PCI-32765 suppressed this and instead enhanced expression of T H 1 cytokines ( Fig. 4I ). As B cell-derived immune complexes promote macrophage T H 2 cytokine expression ( 8 ), these results indicate that B cells promote the immunosuppressive, protumor properties of macrophages in a manner that depends on BTK in both B cells and macrophages.
To evaluate the relative contributions of BTK in B cells and macrophages during tumor progression in vivo , B cells isolated from spleens of PDAC (p53 2.1.1)-bearing animals or Gr1 −
CD11b
+ myeloid cells ( Supplementary Fig. S5A ) isolated from tumors of PDAC (p53 2.1.1)-bearing animals were incubated with PCI-32765 or vehicle, mixed with tumor cells, and implanted in animals. Untreated B cells and myeloid cells had no signifi cant effect on tumor growth, whereas pretreatment of B cells or myeloid cells with BTK inhibitor prior to implantation signifi cantly suppressed tumor growth ( Fig. 5A ) . These results support the hypothesis that BTK in both B cells and myeloid cells promotes PDAC tumor growth.
As neither BTK nor PI3Kγ inhibitors directly affected the viability of macrophages ( Supplementary Fig. S5B ) or PDAC tumor cells ( Supplementary Fig. S5C and S5D ), we evaluated whether PI3Kγ regulated BTK activity during PDAC growth in vivo by systemically treating WT and p110γ −/− mice bearing p53 2.1.1 PDAC tumors with or without PCI-32765 ( Fig.  5B ) . Analogous to clinical scenarios observed in patients ( 31 ), mice receiving PCI-32765 exhibited transient lymphocytosis in the peripheral blood of tumor-bearing mice that resolved by the study termination ( Supplementary Fig. S5E ). PDAC tumor growth was similarly suppressed in p110g −/− animals and in WT mice treated with PCI-32765, whereas PCI-32765 treatment of p110γ −/− mice had no additive effect on tumor growth ( Fig. 5C ) . Importantly, p110g deletion and PCI-32765 inhibitor treatment suppressed B-cell and CD11b
+ myeloid cell infi ltration ( Fig. 5D and E ; Supplementary Fig. S5F ) as predicted by results from the in vitro cell adhesion studies ( Fig. 4A and B ) . p110g deletion and PCI-32765 treatment also increased CD8
+ T-cell presence in tumors ( Fig. 5F ). To evaluate the effect of combined treatment of PDAC tumors with PI3Kγ and BTK pharmacologic inhibitors, we treated mice bearing orthotopic p53 2.1.1 PDAC tumors with PI3Kγ and BTK inhibitors alone, together, or each in combination with gemcitabine (Gem; Fig. 5G ). TG100-115 and PCI-32765 both suppressed PDAC tumor growth, as refl ected in weights of pancreata 28 days after inoculation, but the combination of the two inhibitors had no additive effect ( Fig. 5G ) . Gem monotherapy suppressed tumor growth as measured by pancreas weight, whereas Gem plus TG100-115 or Gem plus PCI-32765 had no additional impact on overall pancreas weight ( Fig. 5G ) . However, histologic examination of end-stage tumors revealed little residual live tumor in pancreata treated with Gem plus PCI-32765 or TG100-115, indicating additive effects of the two therapies with Gem ( Fig.  5H and I ) . Importantly, PI3Kγ and BTK inhibitors suppressed CD11b + myeloid cell infi ltration ( Fig. 5J ; Supplementary Fig.  S5G ) and increased CD8
+ T-cell residency of tumors ( Fig. 5J ), similar to results observed in Fig. 5E and F . The combination of PI3Kγ and BTK inhibitors had no additional effects beyond those of each inhibitor alone, supporting the conclusion that PI3Kγ and BTK regulate the same pathway in vivo as well as in vitro ( Fig. 4E-H ) . In addition, all Gem-treated pancreata exhibited fewer CD11b + and CD8 + T cells than other treatments, as very little tumor tissue remained in these pancreata after 28 days ( Fig. 5I-K ) . As PI3Kγ and BTK inhibition suppressed T H 2 and stimulated T H 1 cytokine expression in in vitro cultured macrophages ( Fig. 4E-I ), in the tumor microenvironment ( Fig. 5L ) , and in tumor-derived myeloid cells ( Supplementary Fig. S5H ), these studies indicate that BTK and PI3Kγ regulate macrophage and T-cell programming in vivo as well as in vitro . Together these data support the conclusion that PI3Kγ and BTK promote a pathway leading to T H 2 polarization during PDAC progression. Furthermore, these data indicate that PI3Kγ and BTK inhibitors could be useful therapeutic approaches to treat early PDAC tumors.
Clinically, patients with PDAC typically present at late stage; thus, we sought to determine if therapeutic administration of PCI-32765 was effi cacious in late-stage PDAC tumors as monotherapy, or in combination with Gem ( Fig. 6A ) . PDAC growth in mice treated with combination PCI-32765/Gem administered at a late stage resulted in signifi cantly reduced tumor size at end stage ( Fig. 6B ) . Decreased tumor burden was associated with reduced presence of CD45 + leukocytes ( Fig. 6C ; Supplementary Fig. S6A ), associated with dynamic changes in the B-cell compartment whereby Gem treatment reduced the presence of memory B cells, BTK inhibitor (BTKi) resulted in increased frequency of T2 and B1b cells and reduced frequency of follicular and marginal zone B cells ( Supplementary Fig. S2D ), and decreased desmoplasia ( Fig.  6D ; Supplementary Fig. S6A ). Importantly, we also observed a signifi cant increase in the intratumoral frequency of granzyme B + T cells/mm 2 in treated tumors depicted in C. L, log base 2 fold change in gene expression in tumors between control and TG100-115 or control and PCI-32765 treatments ( n = 15). mRNAs for which TG100-115-treated tumors showed statistically signifi cant differences from control tumors are shown. Data shown are mean ± SEM of biologic replicates and were validated in 3 or more separate experiments. Signifi cance testing was performed by one-way ANOVA with Tukey post hoc testing for multiple pairwise testing or by Student t test, where P > 0.05 unless other specifi ed, *, P < 0.05; **, P < 0.01; ***, P < 0.001. ns , not statistically different. For A, C, E-G, J and K, each data point refl ects an individual tumor with statistical means shown. For mRNA expression studies, P < 0.01 unless otherwise indicated. 
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+ T cells. Data from 2 independent experiments are shown. Statistical signifi cance was determined using the Student t test or one-way ANOVA when analyzing more than two groups. I, percentage change in Ink4 2.2 tumor size from days 14 to 27 after implantation measured by ultrasonography and assessed following treatment with vehicle (−), PCI-32765, or Gem, and combinations in mice also administered depleting monoclonal antibodies for CD8 + (αCD8) T cells as indicated. Data from 2 independent experiments are shown. *, P < 0.05; **, P < 0.01; ***, P < 0.001. For B-C and E-G and I, each data point refl ects an individual tumor, with statistical means shown. ( Fig.  5L ) . This increased presence of effector CD8 + T-cell phenotypes was functionally signifi cant as CD8 + T-cell depletion reinstated tumor growth to levels similar to Gem-treated mice ( Fig. 6I ; Supplementary Fig. S6C ), without reinstating the CD45 + leukocyte infi ltration ( Fig. 6C ) or desmoplasia ( Fig. 6D ) observed in untreated tumors. Taken together, these results indicate that myeloid cell PI3Kγ activates BTK, thereby promoting myeloid cell recruitment to PDACs and T cellmediated immune suppression, and, importantly, indicate that pharmacologic inhibition of PI3Kγ or BTK activates a T H 1 immune response that suppresses tumor growth.
DISCUSSION
Pancreatic ductal adenocarcinoma is traditionally thought to be an immunologically silent malignancy, but recent therapeutic strategies have demonstrated that effective immunemediated tumor cell death can be invoked to combat disease dissemination (32) (33) (34) . The fundamental principle of these strategies is that CD8 + T-cell phenotypes was also observed midway through therapy, and thus consistent with other reports regarding CD8 + T-cell responses to various immunotherapies ( 35 ) . Based on these data and reports from other groups ( 36, 37 ), we anticipate that targeted inhibition of BTK with therapies like ibrutinib may synergize with immune checkpoint inhibitors and/or select anticancer vaccines to further bolster T-cell activation for long-term durable antitumor immunity ( 36 ) . Notably, this hypothesis is currently being tested in patients with PDAC and squamous cell carcinoma of the head and neck in two clinical trials (ClinicalTrials.gov Identifi ers: NCT02436668 and NCT02454179).
Although protumorigenic activities of B cells have not been widely investigated, we and other groups have reported direct and indirect protumorigenic roles for tumor-infi ltrating as well as peripheral B cells. In squamous carcinomas and melanomas, humoral immunity and IL10-secreting B1 cells induce T H 2-type programing of diverse myeloid cell types that foster tumor angiogenesis and CD8 + T-cell suppression ( 9 , 19 , 38, 39 ) . In B cell-infi ltrated prostate cancers ( 40 ) , immunosuppressive B cells and plasmocytes promote survival of androgen-independent prostatic epithelial cells via lymphotoxin-mediated NFκB regulation ( 41 ) , and inhibit the effi cacy of immunogenic CTX by IL10 and immune checkpoint-mediated suppression of CTLs ( 42 ) Supplementary Fig. S2E ), we anticipate operative activities for these B-cell subsets either in directly driving PDAC-associated T-cell suppression or in regulating CTL-mediated responses to cytotoxic therapy. At earlier stages of PDAC progression, however, IL35-producing B cells promote RAS-driven neoplasia ( 44 ) and B1b cell recruitment that are regulated by oxygen-sensing programs, that together slow early PDAC progression ( 45 ) , and consistent with our results revealing dampened PDAC growth in B cell-defi cient mice ( Fig. 2 ) . Together, these studies support both direct and indirect effects of B cells in regulating discrete aspects of tumorigenesis culminating in regulation of T-cell responses to neoplasia and cytotoxic therapy.
While identifying BTK as a B cell-intrinsic target, studies herein further identify macrophage BTK, and its regulation by FcRγ-and PI3Kγ-mediated signaling, with subsequent effects on macrophage polarization, immune suppression, and induction of desmoplastic stroma. Although one prior study linked the class IA PI3Ks to BTK activation in B cells, recent studies have reported that these proteins regulate similar but distinct signaling pathways in B cells ( 33, 34 ) . Our studies instead reveal the selective role of the class IB PI3K isoform PI3Kγ in regulating BTK to control the macrophage response to the tumor microenvironment. PDACs from BTKi and PI3Kγ inhibitor-treated mice exhibited a T H 1-polarized phenotype with mRNAs encoding stimulators of CD8 + T-cell cytotoxic activity. These observations are similar to antipathogen immunologic states and are necessary for immunogenic cell death of tumor cells ( 46 ) , further supporting the hypothesis that BTK signaling regulates macrophage functionality and ultimately immunosuppression in PDAC tumors. Enhanced antitumor responses were observed when tumor-bearing mice were treated with BTKi therapy for an extended period of time commencing when PDAC tumors were small, as compared with later/larger stage tumors, supporting the general tenet that earlier detection and therapy in PDAC improves outcome.
Regarding BTK-regulated desmoplastic responses in PDACs, data presented herein are consistent with reported roles for macrophages in regulating muscle fi brosis and pancreatitis-associated fi brosis via pathways involving Arginine, TGFβ, MMP9, IL10, and other T H 2-type proteins ( 47, 48 ) . Masso-Valles and colleagues also recently reported an important role for mast cells expressing BTK in regulating desmoplastic stroma of PDAC tumors ( 37 ) 
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of degranulating mast cells within tumor stroma (Supplementary Fig. S6D ). Thus, if BTK regulates mast cell-induced desmoplasia, it likely does so via regulation of a protein secretion pathway, as opposed to a degranulation-mediated mechanism. Moreover, because CD8 + T-cell depletion of PCI-32765/Gem-treated mice reversed the benefi t of combination therapy ( Fig. 6I ) , without affecting decreased desmoplasia of treated tumors ( Fig. 6D ) , these data indicate that decreased PDAC tumor growth due to BTK inhibition is dependent on B-cell and/or myeloid cell reprogramming and bolstering of T H 1-type immune responses, and independent of the desmoplasia that is characteristic of PDAC tumors.
Macrophage activation and polarization state are subject to a multitude of signals distinct in various tumor microenvironments. In mammary carcinomas, macrophages are recruited to tumor parenchyma by CSF1 expressed by mammary epithelial cells ( 49 ) and then polarized to a T H 2 effector state following stimulation by IL4 produced by infi ltrating CD4 + T cells ( 50, 51 ) . T H 2-skewed macrophages in turn indirectly regulate CD8
+ T-cell functionality via their high-level expression of IL10, thereby impairing DC maturation and expression of IL12 ( 20 ) . In contrast, macrophages in SCCs acquire a protumoral T H 2-type phenotype following Ig-containing immune complex activation of FcγR receptors ( 19 ) , which in turn represses expression of macrophage-derived chemokines required for CD8 + T-cell infi ltration ( 9 ) . Whereas some of this same biology is preserved between pancreas and cutaneous microenvironments, other facets may play a more signifi cant role in the pancreas, including mechanisms regulating B1b-cell recruitment into areas of hypoxia ( 45 ) , and/or downstream of oncogenic RAS and CXCL13 ( 44 ) . Future studies will determine why these tissue-specifi c differences exist, the appropriate patient populations likely to respond to these immunotherapy strategies, molecular mechanisms underlying paracrine BTK regulation of CD8 + T-cell functionality, and the degree to which mast cells and macrophages differentially play a role downstream of BTK in regulating desmoplasia associated with PDAC tumorigenesis. As the BTK inhibitor ibrutinib is FDA approved for the treatment of leukemia ( 27 ) , our studies indicate that BTK inhibitors could be rapidly evaluated as new therapeutic agents for pancreatic cancer.
METHODS
Freshly Isolated Human PDAC Samples and Peripheral Blood
All human samples for IHC, pathology, FACS, and plasma analysis were obtained and studied under informed consent in accordance with the Declaration of Helsinki and acquired through the Oregon Pancreatic Tumor Registry and IRB protocol #3609.
Human PDA Tissue Microarray
Microarray data refl ecting CD20 and Ig mRNA in human tumor samples were queried from a commercially available data set (BioExpress System, Gene Logic) originally generated on the Human Genome U133 Plus 2.0 Array (Affymetrix) and normalized by standard robust multichip average procedure. A single probe set of the highest variance among samples was chosen to represent CD20 (228592_at; MS4A1) and Ig (211430_s_at; IGHG1, IGHG2, IGHV4-31, IGHM), respectively. To ensure data consistency, results from additional probe sets were compared with a single probe set. Median value was used to calculate fold change of expression in tumor tissue compared with normal tissue. Statistical analyses were performed using the Wilcoxon rank-sum test to compare mRNA expression levels to their corresponding normal tissue controls.
Immunohistochemistry and Immunofl uorescence
Detailed procedures are provided in the Supplementary Methods.
Cell Lines
Ink4 2.2 and p53 2.1.1 cell lines were derived from primary PDAC tumors (FVB/N) of male transgenic Pdx-Cre; LSL-Kras
G12D mice harboring null mutations in Trp53 and Trp16
Ink4a (10) (11) (12) (13) (14) (15) (16) . Passage 3 of the cell lines was obtained in 2011 directly from the Hanahan laboratory, where they were derived and initially expanded. mCherry transfectants were expanded and frozen at low passage for use in the Coussens and Varner labs. Cells used in these studies were authenticated by gene expression in 2012 (RNA sequencing), whole exome analysis (in 2015), and BTK inhibitor sensitivity analyses (2013) . All cell lines were tested for Mycoplasma contamination and grown in DMEM/10% FBS/1.0% penicillin and streptomycin on plastic coated with 50 μg/mL rat tail collagen I (BD Biosciences).
Animal Husbandry and In Vivo Studies
All animal experiments were performed with approval from the Institutional Animal Care and Use Committees of the University of California, San Diego, or Oregon Health and Science University. Generation and characterization of B cell-defi cient JH −/− (deletion in the J segment of the Ig heavy-chain locus and hence expressing no IgM or IgG and having no mature B cells), FcRγ −/− , and p110γ −/− mice have been described previously ( 17, 18 , 25 ) . All mice used for orthotopic implantation of PDAC cells were male FVB/n, 7 to 12 weeks of age. Mice receiving monoclonal antibodies for cellular depletion and/or cytokine neutralization were administered i.p. αCD8 (2.43, BioXcell) was administered on days 15, 20, and 25 after implantation at 500 μg/mouse; and αCSF1 (clone, BioXcell) was administered at 1.0 mg/ mouse on day 21 and 500 μg/mouse on day 26. PCI-32765 (BTKi) was delivered ad libitum in drinking water at 0.16% w/v in a 2.0% β-hydroxycyclodextrin (Sigma) solution beginning on day 18, and continued until the end of the study. Gemcitabine was administered i.v. at 15 mg/kg on days 18, 22, and 26 after implantation. Alternatively, FVB/n mice inoculated orthotopically with p53 2.1.1 PDAC cells were treated from day 7 with PCI-32765 (0.016% w/v in 2.0% β-hydroxycyclodextrin ad libitum in drinking water) or TG100-115 (2.5 mg/kg i.p., b.i.d.) with or without gemcitabine (15 mg/kg on days 7, 10, 13, 16, 19, 22 , and 25 after implantation). Prior to surgery, mice were anesthetized with isofl uorane, and abdominal hair surrounding the surgical site were removed. A left abdominal fl ank incision (1.5 cm) was made, and spleen and adherent pancreas were exteriorized. PDAC cells (1.0 × 10 3 cells), mixed with 50% Matrigel and 50% serum-free DMEM in a total volume of 30 μL, were injected orthotopically into the tail of the pancreas of syngeneic 7-to-12-week-old male mice using a 30-gauge insulin needle, resulting in the appearance of a fl uid bleb. Pancreas and spleen were then returned to their original position within the peritoneal cavity, followed by suture of the peritoneum and stapling of the skin. Staples were removed 7 days later, and tumor growth was monitored in situ using a Vevo 2100 small animal ultrasound (Visual Sonics) at days 14 and 27 following implantation. PDAC tumors were quantitated with ultrasound based on area (mm 2 ) of the largest face of the tumor and percent change from days 14 to 27 was graphed, by weight in grams, or morphometrically using serial hematoxylin and eosin (H&E)-stained tissue sections by evaluating tumor area every 500 μm through the entire tissue depth and calculating the average 
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tumor area/section. Tissues were formalin-fi xed or frozen in TissueTek Optimal Cutting Temperature (O.C.T.) medium for histologic analysis. RNA was isolated from tissues fl ash-frozen in liquid nitrogen using the methods described for macrophage polarization.
Peripheral Blood Analysis
Blood was collected via cardiac puncture at necropsy or by saphenous vein at specifi c time points during the study and placed into EDTA-coated tubes to prevent clotting. Complete blood count analysis was acquired on a Cell Dyn 3700 analyzer. Plasma was collected by spinning whole blood at 13,000 RPM for 5 minutes, then cell-free supernatant was collected and snap-frozen for later analysis.
ELISA
Plasma from mice was thawed and diluted at 1:10,000 for assay of Ig levels and specifi c isotype. Concentrations of Ig in mouse plasma were determined using a standard curve and ELISA reagents from Southern BioTech. Human IgG was analyzed via the Human IgG Subclass Profi le Kit from Novex-Life Technologies. Human samples were courtesy of the Oregon Pancreas Tumor Registry (OPTR). Data are shown as the fold increase relative to tumor-naïve mice.
Statistical Considerations
For all in vitro studies, experiments were performed three or more times with 3 or more biological replicates per experiment group. In vivo experiments were performed at least twice, with 10 to 15 randomly assigned mice/group for orthotopic tumor studies in WT and p110γ −/− mice, and in mice treated with vehicle, PCI-32765, and TG100-115. A sample size of 15 mice/group provided 80% power to detect a mean difference of 1 standard deviation (SD) between two groups (based on a two-sample t test with two-sided 5% signifi cance level). Prior to statistical analyses, data were examined for possible outliers using the Grubbs test. Data were normalized to the standard where applicable. Signifi cance testing was performed by one-way ANOVA with Tukey post hoc testing for multiple pairwise testing or by parametric or nonparametric Student t test as appropriate. A two-sample t test (two groups) and ANOVA (multiple groups) were used when data were normally distributed, and a Wilcoxon rank-sum test (two groups) when data were not. All mouse studies were randomized for treatment by imaging all mice at day 14 after implantation and equally distributing mice into appropriate groups based on tumor size so that all groups began with a similar mean average (10-11 mm 2 ) prior to treatment. Blinded assignment of mice into treatment groups, tumor measurement, and tumor analysis was performed by coding mice with randomly assigned mouse numbers, with the key unknown to operators until experiments were completed. Treatment studies were further blinded to evaluate tumor growth in response to therapy by having one investigator implant the mice and treat them while another investigator performed imaging at the indicated time points.
Additional detailed methods can be found in the Supplementary Methods. 72h (n=3). Thiazolyl blue tetrazolium bromide (5.0 mg/ml, Sigma) was incubated with cells and solubilized with DMSO.
Disclosure of Potential Confl icts of Interest
Absorbance was determined at 560 nm. 
